AB2056

Anti-TRAIL antibody

Be the first to review this product! 리뷰 제출

(10 제품이 사용된 논문 )

Rabbit Polyclonal TRAIL antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 10 publications. Immunogen corresponding to Synthetic Peptide within Human TNFSF10 aa 250-300.

대체 명칭 보기

CD253, APO2L, TRAIL, TNFSF10, Tumor necrosis factor ligand superfamily member 10, Apo-2 ligand, TNF-related apoptosis-inducing ligand, Apo-2L, Protein TRAIL

4 이미지

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB2056)

IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB2056)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) of human brain tissue staining TRAIL with ab2056 at 20µg/ml

IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB2056)

Immunohistochemistry of TRAIL in human brain tissue with TRAIL antibody at 20 µg/ml.

Unknown

Western blot - Anti-TRAIL antibody (AB2056)

Western blot analysis of HeLa cell lysate containing 10, 2.5, or 1 ng of recombinant protein including extracellular domain of TRAIL with anti-TRAIL at 1 µg/ml Western blot analysis of HeLa cell lysate containing 10, 2.5, or 1 ng of recombinant protein containing extracellular domain of TRAIL with anti-TRAIL at 1 µg/ml.

All lanes:

Western blot - Anti-TRAIL antibody (ab2056)

Predicted band size: 32 kDa

false

Unknown

Western blot - Anti-TRAIL antibody (AB2056)

Western Blot of human brain lysate labeling TRAIL with Anti-TRAIL antibody (ab2056) at (1) 2.5 and (2) 5 μg/ml.

All lanes:

Western blot - Anti-TRAIL antibody (ab2056)

Predicted band size: 32 kDa

false

주요 정보

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

Reacts with

Human

Applications

WB, IHC-P

applications

Immunogen

Synthetic Peptide within Human TNFSF10 aa 250-300. The exact immunogen used to generate this antibody is proprietary information.

P50591

style

left-column

대체품

Primary Antibodies

AB9959

Anti-TRAIL antibody

Sandwich ELISA - Anti-TRAIL antibody (AB9959)

Primary Antibodies

AB2219

Anti-TRAIL antibody [2E5]

Primary Antibodies

AB95532

PE Anti-TRAIL antibody [N2B2]

Flow Cytometry - PE Anti-TRAIL antibody [N2B2] (AB95532)

Primary Antibodies

AB231063

Anti-TRAIL antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB231063)

보완 제품

Assay Kits

AB46074

Human TRAIL ELISA Kit (CD253)

ELISA - Human TRAIL ELISA Kit (CD253) (AB46074)

Primary Antibodies

AB32042

Anti-Cleaved Caspase-3 antibody [E83-77]

20ul selling size|RabMAb|Recombinant|KO Validated

Western blot - Anti-Cleaved Caspase-3 antibody [E83-77] (AB32042)

Primary Antibodies

AB202068

Anti-Caspase-9 antibody [EPR18107]

20ul selling size|RabMAb|Recombinant|KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Caspase-9 antibody [EPR18107] (AB202068)

Primary Antibodies

AB32537

Anti-ERK1 antibody [Y72]

Flow Cytometry (Intracellular) - Anti-ERK1 antibody [Y72] (AB32537)

Primary Antibodies

AB8416

Anti-DR5 antibody

Immunocytochemistry - Anti-DR5 antibody (AB8416)

style

left-column

Reactivity 정보

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500", "WB-species-notes": "<p>Gives a 32 kD band which represents the membrane-bound form of TRAIL.</p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "20 µg/mL", "IHCP-species-notes": "<p></p>" } } }

style

left-column

제품 세부 정보

Ligand for DR4 and DR5.

style

left-column

특성 및 보관 정보

제형

Liquid

Purification 테크닉

Affinity purification

보관 버퍼

pH: 7.2 Preservative: 0.02% Sodium azide

배송 시 보관 조건

Blue Ice

적절한 단기 보관 조건

+4°C

적절한 장기 보관 조건

-20°C

분주 정보

Upon delivery aliquot

보관 정보

Avoid freeze / thaw cycle

style

left-column

추가 정보

This supplementary information is collated from multiple sources and compiled automatically.

TRAIL also known as TNF-related apoptosis-inducing ligand plays an important role in inducing apoptosis. This protein has a mass of around 32 kDa and is expressed across various tissues including immune cells. TRAIL interacts with specific receptors on the cell surface to initiate a signaling cascade that results in programmed cell death. It is an attractive therapeutic target because of its selective ability to induce apoptosis in cancer cells while sparing most normal cells.

Biological function summary

TRAIL's function extends beyond inducing cell death. It is an important member of the tumor necrosis factor (TNF) superfamily which regulates immune responses and inflammation. TRAIL can form a homotrimeric complex allowing it to bind effectively to death receptors on target cells specifically DR4 and DR5 triggering a series of downstream signaling events. This interaction is significant in modulating immune surveillance and tumor suppression.

Pathways

TRAIL is integral to both intrinsic and extrinsic apoptosis pathways. Through these pathways TRAIL is closely related to FADD and caspase-8 which are important for apoptosis induction. The extrinsic pathway involves binding to TRAIL death receptors leading to DISC formation while the intrinsic pathway involves mitochondrial events mediated by members of the Bcl-2 protein family.

TRAIL has a significant connection with cancer and autoimmune diseases. TRAIL plays a dual role in cancer where it acts as a tumor suppressor but can also promote tumor progression if cancer cells become resistant to its effects. In cancer TRAIL’s interaction with proteins like FLIP can alter the apoptotic potential of the cells. In autoimmune diseases TRAIL's dysregulation can contribute to tissue damage due to increased immune activity highlighting its complex role in maintaining immune balance.

style

left-column

style

left-column

제품 프로토콜

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

타겟 정보

Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed : 10549288, PubMed : 26457518). Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis.

See full target information TNFSF10

style

left-column

제품이 사용된 논문 (10)

Recent publications for all applications. Explore the 전체 목록 and refine your search

Cancer immunology, immunotherapy : CII 74:47 PubMed39751958

2025

Distinct immune signatures for predicting the immunotherapy efficacy of esophageal squamous cell carcinoma or adenocarcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Peng Wu,Guohui Qin,Jinyan Liu,Qitai Zhao,Xueke Zhao,Xin Song,Lidong Wang,Shengli Yang,Yi Zhang

Discover oncology 15:45 PubMed38383815

2024

TRAIL predisposes non-small cell lung cancer to ferroptosis by regulating ASK-1/JNK1 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaofang Liu,Huiqian Deng,Mi Huang,Wei Zhou,Yilin Yang

Scientific reports 14:946 PubMed38200037

2024

Optimization of extracellular vesicles preparation from saliva of head and neck cancer patients.

Applications

Unspecified application

Species

Unspecified reactive species

Luisa Tengler,Moritz Tiedtke,Julia Schütz,Karen Bieback,Stefanie Uhlig,Marie-Nicole Theodoraki,Katja Nitschke,Thomas Stefan Worst,Elena Seiz,Claudia Scherl,Nicole Rotter,Sonja Ludwig

International journal of oncology 63: PubMed37503786

2023

Modulation of PD‑L1 expression by standard therapy in head and neck cancer cell lines and exosomes.

Applications

Unspecified application

Species

Unspecified reactive species

Annette Affolter,Kai Liebel,Luisa Tengler,Elena Seiz,Moritz Tiedtke,Alexya Azhakesan,Julia Schütz,Marie-Nicole Theodoraki,Johann Kern,Arne M Ruder,Jens Fleckenstein,Cleo-Aron Weis,Karen Bieback,Benedikt Kramer,Anne Lammert,Claudia Scherl,Nicole Rotter,Sonja Ludwig

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 34:211-220 PubMed36511604

2022

Raw Lacquer Extract from Toxicodendron vernicifluum in Combination with ONC201 Enhances the Inhibitory Effects on Colorectal Cancer Cell Activity.

Applications

Unspecified application

Species

Unspecified reactive species

Zhezhu Jin,Yongjun Jin

Marine drugs 20: PubMed36286419

2022

Cytotoxic Potential of the Marine Diatom : Insights into Bioactivity of 24-Methylene Cholesterol.

Applications

Unspecified application

Species

Unspecified reactive species

Adele Cutignano,Mariarosaria Conte,Virginia Tirino,Vitale Del Vecchio,Roberto De Angelis,Angela Nebbioso,Lucia Altucci,Giovanna Romano

Cancers 13: PubMed33922569

2021

Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients.

Applications

Unspecified application

Species

Unspecified reactive species

Eleni-Kyriaki Vetsika,Priyanka Sharma,Ioannis Samaras,Alexandra Markou,Vassilis Georgoulias,Theresa L Whiteside,Athanasios Kotsakis

Oncotarget 9:27233-27241 PubMed29930761

2018

Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations.

Applications

Unspecified application

Species

Unspecified reactive species

Matias Eliseo Melendez,Renato José Silva-Oliveira,Anna Luiza Silva Almeida Vicente,Lidia Maria Rebolho Batista Arantes,Ana Carolina de Carvalho,Alberto Luis Epstein,Rui Manuel Reis,André Lopes Carvalho

Clinical cancer research : an official journal of the American Association for Cancer Research 23:4843-4854 PubMed28400428

2017

Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Sonja Ludwig,Theofanis Floros,Marie-Nicole Theodoraki,Chang-Sook Hong,Edwin K Jackson,Stephan Lang,Theresa L Whiteside

Oncology reports 27:39-44 PubMed21993926

2011

TRAIL produced from multiple myeloma cells is associated with osteolytic markers.

Applications

Unspecified application

Species

Unspecified reactive species

Yawara Kawano,Shikiko Ueno,Masahiro Abe,Yoshitaka Kikukawa,Hiromichi Yuki,Kenichi Iyama,Yutaka Okuno,Hiroaki Mitsuya,Hiroyuki Hata

제품이 사용된 논문 모두 보기

style

left-column

style

left-column

style

right-column

Product promise

저희는 고품질 시약으로 고객님의 연구를 서포트하고자 최선을 다하고 있으며, 모든 단계에서 함께 하겠습니다. 만약 제품이 기대한 성능을 보이지 않을 경우에도 Product Promise로 보호받으실 수 있습니다.

자세한 내용은 이용 약관을 확인해 주세요.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com